KLUS Pharma is the US subsidiary of Kelun-Biotech, a China-based corporation with a broad pipeline targeting unmet needs in oncology and other serious diseases.
KLUS Pharma is based in Cranbury, NJ, and is the wholly-owned U.S. subsidiary of Kelun-Biotech, a corporation based in Chengdu, China.
We strive to discover and develop innovative biologics for the treatment of cancer and other serious diseases, addressing unmet needs and creating affordable medicines.
Our antibodies undergo affinity maturation, humanization, and Fc engineering, generating lead candidates with optimal efficacy and safety.
Our platform supports a wide variety of bispecific designs which allows for flexibility in selecting the optimal design based on intended MOA.
Dec 22, 2022
Merck and Kelun-Biotech announced that the companies have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer.